
Call for Pilot and Feasibility Projects

Introduction
The Frontiers in Congenital Disorders of Glycosylation Consortium requests full proposals for funding during the 2019-2020 grant year. These awards are intended to support projects that will provide preliminary data for new, extramural grant submissions. The review criteria will emphasize innovation and the potential of the project, if successful, to have a significant impact on an important research problem. Funds will be available for one to two awards with up to $50,000 in direct costs for each award. The duration of the awards will be 12 months.

Background
Frontiers in Congenital Disorders of Glycosylation Consortium (FCDGC) is one of the 20 federally funded consortia to advance medical research on rare diseases by providing support for clinical studies and facilitating collaboration, study enrollment and data sharing.

Eva Morava-Kozicz, M.D., Ph.D., Clinical Genetics, is the Principal Investigator and Director of the Frontiers in Congenital Disorders of Glycosylation Consortium.

The purpose of the FCDGC program is to facilitate the development of pioneering research, clinical trials, training and outreach in the area of congenital disorders of glycosylation.

The grant (U54NS115198) is funded by the National Institute of Neurological Disorders and Stroke, coordinated via National Center for Advancing Translational Science and originates from but originates from the NIH Director’s Common Fund.

Program Goal
The FCDGC provides funds for projects that will exclusively focus on CDG related science and it is meant to produce preliminary data supporting areas of research that are either new in the CDG field or new to an established investigative team. We will especially focus on projects that have the potential for high-impact on CDG patient care. The scope of projects supported by this P&F award mechanism will include any step of the CDG care continuum, ranging from novel concepts in clinical management,
developing novel diagnostics, as well as exploring pathomechanisms and new therapeutics (animal or human studies) in CDG. FCDGC will value proposals that are in the high risk, high impact category. The consortium also aims to form new multidisciplinary collaborations that will enhance the integration of the techniques offered at the participating institutions (list below) that will benefit multiple investigators. Potential applicants are encouraged to explore basic, translational, and clinical research. Extending the collaborative nature of research projects with funds from other mechanisms is encouraged. The strengths of our consortium are extensive expertise in clinical management, expert laboratory science, excellent clinical laboratories, clinical trials with novel therapeutics, rich source of natural history, an ever growing biobank, and access to patient advocacy groups, all focused on improving the diagnosis and clinical management of patients with CDGs.

**Participating Centers in FCDGC**

Below centers participate in the FCDGC consortium. Proposals that develop collaborations with these centers are encouraged, but not necessary. These centers also have expertise in clinical management for CDGs as well as clinical laboratory and research laboratory expertise. This expertise can be leveraged for the proposals. Potential investigators are encouraged to speak with the center’s principal investigator while developing collaborative proposals.

1. Mayo Clinic, Dr. Morava-Kozicz; Morava-Kozicz.Eva@mayo.edu
2. Baylor College of Medicine; Dr. Scaglia; fscaglia@bcm.edu
3. Boston Children’s Hospital; Dr. Berry; Gerard.Berry@childrens.harvard.edu
4. Children’s Hospital of Colorado; Dr. Larson; Austin.Larson@childrenscolorado.org
5. Children’s Hospital of Philadelphia; Dr. He; HeM@email.chop.edu
6. Children’s Hospital of Pittsburgh at the University of Pittsburgh Medical Center; Dr. Vockley; vockleyg@upmc.edu
7. National Human Genome Institute; Dr. Gahl; gahlw@mail.nih.gov
8. Sanford Burnham Prebys Medical Discovery Institute; Dr. Freeze; hudson@sbmpdiscovery.org
9. Seattle Children’s Hospital; Dr. Lam; Christina.Lam@seattlechildrens.org
10. Tulane University Medical School; Dr. Andersson; handers@tulane.edu
11. University of Alabama; Dr. Might; might@uab.edu
12. University of Minnesota Masonic Children’s Hospital: Dr. Sarafoglou; saraf010@umn.edu

**Eligibility**

All basic, translational, or clinical investigators located at institutions within the United States who are eligible to apply as a Principal Investigator for NIH grants. Early stage investigators and investigators who are new to the field of CDG are especially encouraged to apply. Investigators who have extensive research programs in CDGs are generally ineligible for funding (i.e. R01 style grants focused on CDG).

**Funding**
- Up to $50,000 in direct costs for each award.
- Eligible expenses include costs for clinical data collection, sample collection, laboratory data collection, data analysis and animal care. Laboratory data collection is to be performed with FCDGC labs and the expense is covered.
- Investigator effort will not be supported.
- Project duration of one year.
- NIH application guidelines will be followed.

**Review procedure**
Content experts will form the review panel. Recommendations for funding will be forwarded to the national RCMRC Executive Committee, who will make final approvals for funding. Applications will be scored using the current [NIH Scoring System](#).

Review criteria will include the following:

- Alignment with goals of program.
- Scientific merit and innovation.
- Likelihood to support novel research questions that leverage the skills of the FCDGC.
- Likelihood of future extramural funding.
- Feasibility within time and budget proposed.
- Qualifications and scientific environment of the investigators.
- Priority will be given to projects which have samples ready for analysis.

**Application Information**
Applications are due no later than 12/09/2019. Earliest anticipated start date is 02/01/2020.

Applications must include the following components and use [PHS 398 continuation format page](#) unless otherwise specified.

A. Cover letter including project title, principal investigator, co-investigators and affiliations.

B. Abstract — A paragraph summary of the project.

C. Layperson summary — Please provide a two to three sentence summary that could be understood by a lay audience.

D. Specific aims — One page outlining the goals of your project.

E. Research plan — Background, hypothesis, prior work summary, experimental plan, timeline and extramural funding as well as justification for the use of the FCGDC services and resources (includes clinical data collection/storage, sample
collection/storage, laboratory services, data analysis services, etc.). A five page limit is enforced for this section.

F. References cited.

G. Biographical sketches — Please use the PHS 398 biographical sketch format for each PI and Co-Investigator.

H. Resource inventory — List the resources that will be made available for the project.

I. Budget and Justification — Include a budget (budget limit of $50,000 direct per application) and justification. Please use the PHS 398 Detailed Budget for Initial Budget Period format page.

J. Human Subjects and Clinical Trials — The FCDGC will require that all applicants for P&F awards follow the NIH criteria to define and recognize proposals involving human subjects and human clinical trials. We will require any proposal involving human subjects to follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application guide. Applications that are not compliant with NIH human subject and clinical trial policy will not be considered for funding.

K. Inclusion of Women, Children and Minorities — The FCDGC will require that applicants for P&F awards carefully consider the inclusion of women, children, and minorities in clinical studies using relevant NIH guidelines. However, we recognize that given the rare nature of the disease, small size of the awards and their hypothesis generating nature, large diverse sample sizes are not realistic for all human studies.

L. Vertebrate Animals — The FCDGC will require verification that the Institutional Animal Care and Use Committee (IACUC) has reviewed and approved the proposed activity for all P&F awards that utilize vertebrate animals.

Please bundle all application documents into one PDF file. Submit via email to FCDGC@mayo.edu. Please indicate “Frontiers in Congenital Disorders of Glycosylation Consortium Application” in the subject line.

Please contact Eva Morava-Kozicz MD, PhD (Morava-Kozicz.Eva@mayo.edu) to discuss clinical management, natural history and clinical trial expertise for the proposal. Please contact Surendra Dasari, PhD (dasari.surendra@mayo.edu) to discuss clinical laboratory services. Please contact Hudson Freeze, PhD (hudson@sbpdiscovery.org) or Tamas Kozicz, MD, PhD (Kozicz.Tamas@mayo.edu) to discuss research laboratory services.

**Reporting and Tracking of Impact**

Progress reports will be required at the end of the funding period and yearly for two years after the end of the funding period. Information tracked will include the following:
Grants applied for and funded.
Publications.
Impact on career development.
Impact on clinical practice.
Invention disclosures or other commercialization activities resulting.

Publications
The NIH Public Access Policy requires that all publications resulting from NIH funding be uploaded to PubMed Central. The following link will guide awardees through the process of uploading publications.

Awardees must cite the Mayo Clinic Metabolomics Resource Core grant as a funding source in any resulting publications:

This publication was made possible by Frontiers in Congenital Disorders of Glycosylation Consortium through grant number U54NS115198 is funded by the National Institute of Neurological Disorders and Stroke and originates from the National Institutes of Health Director’s Common Fund.

Questions
If you have any questions about the grants or the application process, please contact Dr. Surendra Dasari (dasari.surendra@mayo.edu) or Dr. Eva Morava-Kozicz (Morava-Kozicz.Eva@mayo.edu)